

**AMENDMENTS TO THE SPECIFICATION:**

Please replace paragraph [0036] starting at page 16, line 14 of the substitute specification filed on January 21, 2005 with the following paragraph:

Figure 1 shows the results of a tumor challenge study in which immunization using a hybrid antigen or complex of a hybrid antigen with a heat shock protein was performed, followed seven days later by challenge with a tumor expressing the antigen. In particular, the epitope SIINFEKL (SEQ ID NO:868) and the hybrid antigen NLLRLTGWFFRKSIIINFEKL (SEQ ID NO:881) were assayed.

Please replace paragraph [0100] starting at page 58, line 25 of the substitute specification filed on January 21, 2005 with the following paragraph:

A variety of hybrid antigens were prepared, each comprising a heat shock protein binding domain and a cancer antigen epitope or the model Class I H2-K<sup>b</sup> epitope from ovalbumin, SIINFEKL (SEQ ID NO:868). A peptide linker was included between the two domains. The heat shock protein binding domains used in these experiments were among the following: HWDFAWPW (SEQ ID NO:869), NLLRLTGW (SEQ ID NO:870), FYQLALTW (SEQ ID NO:871) and RKLFFNLRW (SEQ ID NO:872). Linkers were among those ~~described~~ described hereinabove.